Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug ...

Teva Pharmaceutical (NYSE:TEVA) and Alvotech (NASDAQ:ALVO) have launched their biosimilar targeting Johnson & Johnson’s (NYSE ...

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

Teva Pharmaceuticals (TEVA) and Alvotech (ALVO) announced the availability of SELARSDI injection in the U.S., a biosimilar to Stelara for the ...

Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

Alvotech and Teva Pharmaceuticals said on Tuesday that the U.S. FDA has accepted for review a Biologics License Application ...

Teva has not raised capital since it acquired Actavis from Allergan in 2016 - a deal worth nearly $40 billion and for which ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.